All In Biotech

NDA 022460 · Waylis Therap

Jalyn

Dutasteride, Tamsulosin Hydrochloride · Oral · 5-alpha Reductase Inhibitor

Last checked: Nov 20, 2026Latest source record: Dec 29, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Jun 14, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

114

26 Phase 3, 7 recruiting

FAERS reports

1,046

405 serious, 58 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 9, 2026.

JALYN is a combination of dutasteride, a 5-alpha-reductase inhibitor, and tamsulosin, an alpha-adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. ( 1.1 ) Limitations of Use: Dutasteride-containing products, including JALYN, are not approved for the prevention of prostate cancer. ( 1.2 ) 1.1 Benign Prostatic Hyperplasia (BPH) Treatment JALYN (dutasteride and tamsulosin hydrochloride) capsules are indicated for the treatment of symptomatic BPH in men with an enlarged prostate. 1.2 Limitations of Use Dutasteride-containing products, including JALYN, are not approved for the prevention of prostate cancer.

Mechanism: JALYN is a combination of 2 drugs with different mechanisms of action to improve symptoms in patients with BPH: dutasteride, a 5-alpha-reductase inhibitor, and tamsulosin, an antagonist of alpha 1A -adrenoreceptors. Dutasteride Dutasteride inhibits the conversion of testosterone to DHT. DHT is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. Testosterone is converted to DHT by the enzyme 5 alpha-reductase, which exists as 2 isoforms, type 1 and type 2. The type 2 isoenzyme is primarily active in the reproductive tissues, while...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • JALYN · DUTASTERIDE 0.5MG; TAMSULOSIN HYDROCHLORIDE 0.4MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dutasteride" as an intervention, any sponsor and status, largest first.

All 114 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective90
  • dizziness72
  • rash43
  • diarrhoea39
  • fatigue39
  • dyspnoea35
  • fall32
  • erectile dysfunction30
  • pruritus29
  • headache25
  • hypotension25
  • asthenia23

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201012
2011200
2012187
2013109
2014105
2015111
201696
201739
201851
201939
202032
202117
202212
20235
202414
20256
202611

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Jalyn (Dutasteride/Tamsulosin HCl)

2024 spending

$32K

Beneficiaries

21

29 claims

Per beneficiary

$1,535

$21.78 per unit

View as table
YearSpending
2020$1,103,155
2021$935,195
2022$909,866
2023$1,119,872
2024$32,232

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 275 on PubMed

Sponsor: Waylis Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.